Henry Schein vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest dental/medical distributor; recovered from 2023 ALPHV ransomware attack; $12.4B 2024 revenue; digital dentistry platform driving recurring tech revenue.
About
Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, founded in 1932 by Henry Schein in Queens, New York, and headquartered in Melville, New York. The company trades on Nasdaq (HSIC) and generated approximately $12.4 billion in net sales in 2024, serving over one million healthcare practitioners across more than 30 countries. Henry Schein operates through two segments: Health Care Distribution, supplying dental and medical consumables, equipment, and technology; and Technology and Value-Added Services, offering practice management software and digital dentistry solutions under brands like Dentrix, Dexis, and Axium.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.